Immune Modulation by Addition of Oral Lenalidomide to Intravesical BCG (Bacille Calmette-Guerrin) for Therapy of Non-muscle-invasive Transitional Cell Bladder Cancer.

Trial Profile

Immune Modulation by Addition of Oral Lenalidomide to Intravesical BCG (Bacille Calmette-Guerrin) for Therapy of Non-muscle-invasive Transitional Cell Bladder Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Lenalidomide (Primary) ; BCG vaccine
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Feb 2017 Planned End Date changed from 1 Apr 2017 to 1 Nov 2017.
    • 01 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Apr 2017.
    • 11 May 2016 Planned End Date changed from 1 Jun 2016 to 1 Aug 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top